Oxford-AstraZeneca COVID-19 vaccine gets recommendation for emergency use, DCGI to take final call
- InduQin
- Jan 4, 2021
- 1 min read
An expert panel on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on Friday recommended to grant emergency use authorisation for the Oxford COVID-19 vaccine Covishield, being manufactured by Serum Institute of India, sources said on Friday. The Pune-based Serum Institute of India (SII), the world's largest vaccine manufacturer, has tied up with AstraZeneca to manufacture Covishield.
DCGI to give final approval
The application will be sent to Drugs Controller General of India (DCGI) VG Somani for final approval. The approval will pave the way for the vaccine's rollout in India, which also has the highest number of infections in the world, after the US. The rollout will begin from January 6, according to ministry sources.
UK already approved emergency use authorisation of Oxford vaccine
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday had approved the COVID-19 vaccine developed by scientists at Oxford University and produced by AstraZeneca for human use.
The Subject Expert Committee (SEC) on COVID-19 of the CDSCO, which had earlier sought additional safety and immunogenicity data from SII, deliberated on its application seeking emergency use authorisation (EUA) for the shots on Wednesday, and met again on Friday to review the matter.
Comments